Next Article in Journal
Ameliorative Effects of a Polyphenolic Fraction of Cinnamomum zeylanicum L. Bark in Animal Models of Inflammation and Arthritis
Previous Article in Journal
Analysis of the Cytotoxic Potential of Anisomelic Acid Isolated from Anisomeles malabarica
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC

by
Prakash KATAKAM
1,*,
Baishakhi DEY
2,
Nagiat T. HWISA
1,
Fathi H. ASSALEH
1,
Babu R. CHANDU
1,
Rajeev K. SINGLA
3 and
Analava MITRA
2
1
Faculty of Pharmacy, University of Zawia, Az Zawiyah, Libya
2
School of Medical Science & Technology, IIT Kharaghpur, India
3
Division of Biotechnology, Netaji Subhas Institute of Technology, New Delhi, India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2014, 82(3), 617-630; https://doi.org/10.3797/scipharm.1403-20
Submission received: 24 March 2014 / Accepted: 5 May 2014 / Published: 5 May 2014

Abstract

Impurity profiling has become an important phase of pharmaceutical research where both spectroscopic and chromatographic methods find applications. The analytical methodology needs to be very sensitive, specific, and precise which will separate and determine the impurity of interest at the 0.1% level. Current research reports a validated RP-HPLC method to detect and separate valacyclovir-related impurities (Imp-E and Imp-G) using the Box-Behnken design approach of response surface methodology. A gradient mobile phase (buffer: acetonitrile as mobile phase A and acetonitrile: methanol as mobile phase B) was used. Linearity was found in the concentration range of 50–150 μg/mL. The mean recovery of impurities was 99.9% and 103.2%, respectively. The %RSD for the peak areas of Imp-E and Imp-G were 0.9 and 0.1, respectively. No blank interferences at the retention times of the impurities suggest the specificity of the method. The LOD values were 0.0024 μg/mL for Imp-E and 0.04 μg/mL for Imp-G and the LOQ values were obtained as 0.0082 μg/mL and 0.136 μg/mL, respectively, for the impurities. The S/N ratios in both cases were within the specification limits. Proper peak shapes and satisfactory resolution with good retention times suggested the suitability of the method for impurity profiling of valacyclovir-related drug substances.
Keywords: Impurity profiling; Box-Behnken design; Retention time; Validated method; Response Surface Methodology; Valaciclovir Impurity profiling; Box-Behnken design; Retention time; Validated method; Response Surface Methodology; Valaciclovir

Share and Cite

MDPI and ACS Style

KATAKAM, P.; DEY, B.; HWISA, N.T.; ASSALEH, F.H.; CHANDU, B.R.; SINGLA, R.K.; MITRA, A. An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC. Sci. Pharm. 2014, 82, 617-630. https://doi.org/10.3797/scipharm.1403-20

AMA Style

KATAKAM P, DEY B, HWISA NT, ASSALEH FH, CHANDU BR, SINGLA RK, MITRA A. An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC. Scientia Pharmaceutica. 2014; 82(3):617-630. https://doi.org/10.3797/scipharm.1403-20

Chicago/Turabian Style

KATAKAM, Prakash, Baishakhi DEY, Nagiat T. HWISA, Fathi H. ASSALEH, Babu R. CHANDU, Rajeev K. SINGLA, and Analava MITRA. 2014. "An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC" Scientia Pharmaceutica 82, no. 3: 617-630. https://doi.org/10.3797/scipharm.1403-20

APA Style

KATAKAM, P., DEY, B., HWISA, N. T., ASSALEH, F. H., CHANDU, B. R., SINGLA, R. K., & MITRA, A. (2014). An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC. Scientia Pharmaceutica, 82(3), 617-630. https://doi.org/10.3797/scipharm.1403-20

Article Metrics

Back to TopTop